PE20061335A1 - Compuestos derivados de benzodioxano y benzodioxolano como moduladores del receptor 5-ht2c - Google Patents

Compuestos derivados de benzodioxano y benzodioxolano como moduladores del receptor 5-ht2c

Info

Publication number
PE20061335A1
PE20061335A1 PE2006000414A PE2006000414A PE20061335A1 PE 20061335 A1 PE20061335 A1 PE 20061335A1 PE 2006000414 A PE2006000414 A PE 2006000414A PE 2006000414 A PE2006000414 A PE 2006000414A PE 20061335 A1 PE20061335 A1 PE 20061335A1
Authority
PE
Peru
Prior art keywords
benzodioxin
dihydro
amine
methyl
benzodioxane
Prior art date
Application number
PE2006000414A
Other languages
English (en)
Inventor
Dahui Zhou
Gary Paul Stack
Hong Gao
Jonathan Laird Gross
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20061335A1 publication Critical patent/PE20061335A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)

Abstract

REFERIDA A UN COMPUESTO DERIVADO DE BENZODIOXANO DE FORMULA (I), DONDE M ES 1 O 2; n ES 0 0 1; Ar ES FENILO, UN ANILLO CARBOCICLO ARILO O BICICLICO PARCIALMENTE INSATURADO DE 8 A 10 MIEMBROS, HETEROARILO MONOCICLICO DE 5 A 6 MIEMBROS QUE TIENE DE 1 A 4 HETEROATOMOS SELECCIONADOS DE NITROGENO, OXIGENO O AZUFRE, ENTRE OTROS; R1 ES R, CN, HALOGENO, OR, ENTRE OTROS; R ES H, ENTRE OTROS; R2 ES H, ALQUILO C1-C3, O(ALQUILO C1-C3), ENTRE OTROS; R3 Y R4 SON H O ALIFATICO C1-C6. SON COMPUESTOS PREFERIDOS: {[8-(2-FLUORFENIL)-2,3-DIHIDRO-1,4-BENZODIOXIN-2-IL]METIL}AMINA, {[8-(2-CLOROFENIL)-2,3-DIHIDRO-1,4-BENZODIOXIN-2-IL]METIL}AMINA, {[8-(2-METILFENIL)-2,3-DIHIDRO-1,4-BENZODIOXIN-2-IL]METIL}AMINA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS SON AGONISTAS DEL RECEPTOR 5-HT2C Y SON UTILES PARA EL TRATAMIENTO DE LA ESQUIZOFRENIA, OBESIDAD, DEPRESION, ENTRE OTRAS
PE2006000414A 2005-04-22 2006-04-21 Compuestos derivados de benzodioxano y benzodioxolano como moduladores del receptor 5-ht2c PE20061335A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67388405P 2005-04-22 2005-04-22

Publications (1)

Publication Number Publication Date
PE20061335A1 true PE20061335A1 (es) 2006-12-29

Family

ID=36688044

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000414A PE20061335A1 (es) 2005-04-22 2006-04-21 Compuestos derivados de benzodioxano y benzodioxolano como moduladores del receptor 5-ht2c

Country Status (20)

Country Link
US (1) US20060241172A1 (es)
EP (1) EP1871759A1 (es)
JP (1) JP2008538575A (es)
KR (1) KR20080009295A (es)
CN (1) CN101218223A (es)
AR (1) AR054035A1 (es)
AU (1) AU2006239930A1 (es)
BR (1) BRPI0610046A2 (es)
CA (1) CA2605580A1 (es)
CR (1) CR9459A (es)
GT (1) GT200600159A (es)
IL (1) IL186835A0 (es)
MX (1) MX2007013151A (es)
NI (1) NI200700270A (es)
NO (1) NO20075623L (es)
PE (1) PE20061335A1 (es)
RU (1) RU2007139543A (es)
TW (1) TW200720266A (es)
WO (1) WO2006116158A1 (es)
ZA (1) ZA200709043B (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
US20050261347A1 (en) * 2003-10-24 2005-11-24 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US7435837B2 (en) * 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
ES2260563T3 (es) * 2003-11-13 2006-11-01 Ferring B.V. Paquete de blister y forma farmaceutica solida para ello.
TW200612905A (en) * 2004-06-16 2006-05-01 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
KR20070057848A (ko) * 2004-08-24 2007-06-07 얀센 파마슈티카 엔.브이. 항경련제로 유용한 신규 벤조-융합된 헤테로아릴 설파미드유도체
GT200500296A (es) * 2004-10-21 2006-10-02 Sintesis asimetrica de derivados del dehidrobenzofurano
GT200500297A (es) * 2004-10-21 2006-10-27 Sintesis asimetrica de dehidrobenzofuranos sustituidos
EP1874756A1 (en) * 2005-04-22 2008-01-09 Wyeth Chromane and chromene derivatives and uses thereof
EP1871356A1 (en) * 2005-04-22 2008-01-02 Wyeth a Corporation of the State of Delaware Dihydrobenzofuran derivatives and uses thereof
PE20061298A1 (es) * 2005-04-22 2006-12-24 Wyeth Corp Compuestos derivados de dihidrobenzofurano como agonistas del receptor de serotonina 5-ht2c
CA2605554A1 (en) * 2005-04-22 2006-11-02 Wyeth Benzofuranyl alkanamine derivatives and uses thereof as 5-ht2c agonists
BRPI0610028A2 (pt) * 2005-04-22 2010-05-18 Wyeth Corp combinações terapêuticas para o tratamento ou a prevenção de distúrbios psicóticos
US20060258713A1 (en) * 2005-04-22 2006-11-16 Wyeth Treatment of pain
CN101180283A (zh) * 2005-04-22 2008-05-14 惠氏公司 二氢苯并呋喃衍生物和其用途
EP1874292A2 (en) * 2005-04-24 2008-01-09 Wyeth Methods for modulating bladder function
AU2006249577A1 (en) * 2005-05-20 2006-11-30 Janssen Pharmaceutica N.V. Process for preparation of sulfamide derivatives
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US8497298B2 (en) * 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US8937096B2 (en) * 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8492431B2 (en) * 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US8716231B2 (en) * 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8691867B2 (en) * 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
SE528446C2 (sv) * 2006-03-02 2006-11-14 Ferring Int Ct Sa Farmaceutisk sammansättning innefattande desmopressin, kiseldioxid och stärkelse
EP1998764A2 (en) * 2006-03-24 2008-12-10 Wyeth a Corporation of the State of Delaware Methods for treating cognitive and other disorders
AR060493A1 (es) * 2006-04-18 2008-06-18 Wyeth Corp Derivados de benzodioxano y benzodioxolano. procesos de obtencion.
WO2007132841A1 (ja) 2006-05-16 2007-11-22 Takeda Pharmaceutical Company Limited 縮合複素環化合物およびその用途
EP2026790A2 (en) * 2006-05-19 2009-02-25 Janssen Pharmaceutica, N.V. Co-therapy for the treatment of epilepsy and related disorders
CL2007003044A1 (es) * 2006-10-24 2008-07-04 Wyeth Corp Compuestos derivados de benzoxazina; composicion farmaceutica que los comprende; y uso para el tratamiento de un trastorno psicotico, bipolar, depresivo y abuso o dependencia de sustancias entre otros.
TW200823187A (en) * 2006-10-24 2008-06-01 Wyeth Corp Benzodioxane derivatives and uses thereof
CA2695634C (en) 2007-08-06 2018-01-23 Serenity Pharmaceuticals Corporation Methods and devices for desmopressin drug delivery
WO2009063992A1 (ja) 2007-11-15 2009-05-22 Takeda Pharmaceutical Company Limited 縮合ピリジン誘導体およびその用途
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
US20090247616A1 (en) * 2008-03-26 2009-10-01 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety
US20110105462A1 (en) * 2008-04-29 2011-05-05 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Modulators of dopamine neurotransmission
AU2009242095A1 (en) 2008-04-29 2009-11-05 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Modulators of dopamine neurotransmission
KR20100135325A (ko) * 2008-04-29 2010-12-24 엔에스아베 필리알 아프 뉴로서치 스웨덴 아베 스베리게 도파민 신경전달의 조절제
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
DK3225250T3 (da) 2008-05-21 2019-11-04 Ferring Bv Orodispersibel desmopressin til forlængelse af den indledende søvnperiode, som ikke forstyrres af nykturi
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
BRPI0915890A2 (pt) * 2008-06-23 2015-11-03 Janssen Pharmaceutica Nv forma cristalina de (2s)-(-)-n-(6-cloro-2,3-di-hidro-benzo[1,4]dioxin-2-ilmetil)-sulfamida
US8815939B2 (en) * 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
KR20130041225A (ko) * 2010-07-20 2013-04-24 바이엘 크롭사이언스 아게 항진균제로서의 벤조시클로알켄
WO2012030953A1 (en) 2010-09-01 2012-03-08 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
BR112013015973B1 (pt) 2010-12-21 2018-12-11 Colgate-Palmolive Company bifenóis halogenados como agentes antibacterianos.
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
MX2018015872A (es) * 2016-06-29 2019-04-22 Orion Corp Derivados de benzodioxano y su uso farmaceutico.
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US20210052600A1 (en) 2017-12-27 2021-02-25 Takeda Pharmaceutical Company Limited Therapeutic agents for stress urinary incontinence and incotinence of feces
GB201801128D0 (en) * 2018-01-24 2018-03-07 Univ Oxford Innovation Ltd Compounds
WO2020086864A1 (en) * 2018-10-24 2020-04-30 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m1
CN109293480B (zh) * 2018-10-31 2020-10-09 陕西硕博电子材料有限公司 二烯丙基双酚a、制备方法及双马来酰亚胺树脂预聚物
JP2022529781A (ja) 2019-04-17 2022-06-24 コンパス パスファインダー リミテッド サイロシビンによるうつ病及び他の様々な障害の治療
EP4021433B1 (en) 2019-08-26 2023-10-04 Period Pill BV Treatment of menstrual cycle-induced symptoms
JP2023530092A (ja) * 2020-06-08 2023-07-13 タクトジェン インコーポレイテッド 精神障害又は精神高揚に有利なベンゾフラン組成物
CN112121463B (zh) * 2020-09-15 2022-03-22 烟台宁远药业有限公司 一种多取代苯并含氮杂环甲胺的制备方法
CN114890978B (zh) * 2022-04-19 2023-07-25 宿迁医美科技有限公司 酚类化合物及其制备方法和应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2906757A (en) * 1959-09-29 Their preparation
GB1054104A (es) * 1962-07-20
US3872105A (en) * 1973-06-11 1975-03-18 Merrell Inc Richard Derivatives of 1,3-benzodioxole-2-carboxylic acid
US4118507A (en) * 1977-03-17 1978-10-03 Shell Oil Company Benzodioxincarboxamide lipogenesis inhibitors
US5120758A (en) * 1991-02-08 1992-06-09 Ciba-Geigy Corporation Certain benzodioxole, benzodioxane and benzodioxepin derivatives useful as 5-lipoxygenase inhibitors
JP3454531B2 (ja) * 1991-11-07 2003-10-06 三共株式会社 ニトロキシアルキルアミド誘導体
US5731324A (en) * 1993-07-22 1998-03-24 Eli Lilly And Company Glycoprotein IIb/IIIa antagonists
FR2716680B1 (fr) * 1994-02-25 1996-04-05 Adir Nouveaux dérivés de benzodioxane, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
JP3235448B2 (ja) * 1995-03-24 2001-12-04 ダイソー株式会社 １，４−ベンゾジオキサン誘導体の製法
US6514996B2 (en) * 1995-05-19 2003-02-04 Kyowa Hakko Kogyo Co., Ltd. Derivatives of benzofuran or benzodioxole
FR2791675B1 (fr) * 1999-03-30 2001-05-04 Synthelabo Derives de n-[2-(4-aminophenyl) ethyl] -2,3-dihydro-1,4- benzodioxinne-2-methanamine, leur preparation et leur application en therapeutique
GB0007376D0 (en) * 2000-03-28 2000-05-17 Knoll Ag Therapeutic agents
WO2004013120A1 (en) * 2002-07-29 2004-02-12 F. Hoffmann-La Roche Ag Novel benzodioxoles
US20050261347A1 (en) * 2003-10-24 2005-11-24 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US7728155B2 (en) * 2003-10-24 2010-06-01 Wyeth Llc Dihydrobenzofuranyl alkanamines and methods for using same as cns agents
CN100540546C (zh) * 2004-05-05 2009-09-16 弗·哈夫曼-拉罗切有限公司 用于调节5-ht6受体、5-ht2a受体或两者的芳基磺酰基苯并二烷
GT200500297A (es) * 2004-10-21 2006-10-27 Sintesis asimetrica de dehidrobenzofuranos sustituidos
GT200500296A (es) * 2004-10-21 2006-10-02 Sintesis asimetrica de derivados del dehidrobenzofurano
BRPI0610028A2 (pt) * 2005-04-22 2010-05-18 Wyeth Corp combinações terapêuticas para o tratamento ou a prevenção de distúrbios psicóticos
EP1874756A1 (en) * 2005-04-22 2008-01-09 Wyeth Chromane and chromene derivatives and uses thereof
CA2605554A1 (en) * 2005-04-22 2006-11-02 Wyeth Benzofuranyl alkanamine derivatives and uses thereof as 5-ht2c agonists
JP2008538766A (ja) * 2005-04-22 2008-11-06 ワイス 薬物乱用の処置
PE20061327A1 (es) * 2005-04-22 2007-01-02 Wyeth Corp Combinaciones de derivados de benzofurano y un antidepresivo para el tratamiento o la prevencion de la depresion
US20060258713A1 (en) * 2005-04-22 2006-11-16 Wyeth Treatment of pain
PE20061298A1 (es) * 2005-04-22 2006-12-24 Wyeth Corp Compuestos derivados de dihidrobenzofurano como agonistas del receptor de serotonina 5-ht2c
CN101180283A (zh) * 2005-04-22 2008-05-14 惠氏公司 二氢苯并呋喃衍生物和其用途
EP1871356A1 (en) * 2005-04-22 2008-01-02 Wyeth a Corporation of the State of Delaware Dihydrobenzofuran derivatives and uses thereof
MX2007013179A (es) * 2005-04-22 2008-01-16 Wyeth Corp Formas cristalinas de clorhidrato de {[(2r)-7-(diclorofenil)-5- fluoro-2,3-dihidro-1-benzofurano-2-il]metil}amina.
EP1874292A2 (en) * 2005-04-24 2008-01-09 Wyeth Methods for modulating bladder function

Also Published As

Publication number Publication date
GT200600159A (es) 2007-03-14
IL186835A0 (en) 2008-02-09
MX2007013151A (es) 2008-01-16
CA2605580A1 (en) 2006-11-02
BRPI0610046A2 (pt) 2010-05-25
KR20080009295A (ko) 2008-01-28
US20060241172A1 (en) 2006-10-26
NO20075623L (no) 2008-01-17
NI200700270A (es) 2008-06-25
AR054035A1 (es) 2007-05-30
WO2006116158A1 (en) 2006-11-02
JP2008538575A (ja) 2008-10-30
EP1871759A1 (en) 2008-01-02
TW200720266A (en) 2007-06-01
AU2006239930A1 (en) 2006-11-02
CR9459A (es) 2008-02-20
ZA200709043B (en) 2009-09-30
CN101218223A (zh) 2008-07-09
RU2007139543A (ru) 2009-05-27

Similar Documents

Publication Publication Date Title
PE20061335A1 (es) Compuestos derivados de benzodioxano y benzodioxolano como moduladores del receptor 5-ht2c
PE20061297A1 (es) Compuestos derivados de cromano y cromeno moduladores del receptor de serotonina 5-ht2c
PE20070519A1 (es) Derivados de fenilmorfolina y feniltiomorfolina como agonistas de adrenoreceptores alfa 2c
UY29312A1 (es) Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones
PE20091376A1 (es) Derivados de fenilamino como moduladores de beta-amiloide
PE20130375A1 (es) Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos
PE20060777A1 (es) Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
PE20091621A1 (es) Derivados de amina como moduladores de la actividad de tlr y composiciones que los contienen
PE20061106A1 (es) Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida
PE20050142A1 (es) 2-hidroxi-3-diaminoalcanos de benzamida
PE20090813A1 (es) Inhibidores de la 11b-hidroxiesteroide-deshidrogenasa
PE20041040A1 (es) Compuestos derivados de amidas como inhibidores de 11-beta-hidroxiesteroide-deshidroxigenasa de tipo 1
PE20060401A1 (es) Derivados de n-(2-bencil)-2-fenil-butanamidas y propanamidas como moduladores del receptor de androgeno
ECSP055987A (es) Derivados de heteroarilcarbamoilbenceno
PE20021005A1 (es) Quinazolinas como inhibidores de mmp-13
PE20070527A1 (es) Derivados de espirocromanona como agentes inhibidores de la acetil coenzima a carboxilasa
PE20061144A1 (es) DERIVADOS DE PIRROLIDINA Y PIPERIDINA ACETILENO COMO ANTAGONISTAS DE LOS RECEPTORES DE GLUTAMATO METABOTROPICO (mGluRs)
AR058124A1 (es) Derivados de ftalazinona como inhibidores de parp-1
PE20040832A1 (es) Derivados de indolil pirazinona
BRPI0606895A2 (pt) novos compostos com efeito terapêutico
GB0507601D0 (en) Compounds
PE20060623A1 (es) Compuestos de sulfonamida como potenciadores del receptor de glutamato
PE20080889A1 (es) Aminometil-4-imidazoles
PE20060630A1 (es) Amidas sustituidas de acido tienopirrolcarboxilico, amidas del acido pirrolotiazolcarboxilico y analogos relacionados como inhibidores de la caseina cinasa ie
AR045868A1 (es) Proceso para preparar compuestos de ocarbamoilo en presencia de grupo amina activa

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed